Today's Must Read
Novo Nordisk (NVO) Diabetes Drug Victoza is Key to Growth
Enterprise Products (EPD) Increases Quarterly Distribution
Monday, October 10, 2016
Today's Research Daily features new research reports on 16 major stocks, including Alphabet (GOOGL), Novo Nordisk (NVO) and Enterprise Products Partners (EPD).
Google parent Alphabet shares lagged the broader market and the Tech sector this year, but the company remains well positioned for outperformance in the long run given its focus on innovation, strategic acquisitions, the Android OS and a number of other diversification moves. In its Oct 4 event, the tech giant unveiled a range of new products including two smartphones, a 5.0 inch Pixel and a 5.5 inch Pixel XL, and an Android virtual reality headset, Daydream. However, growing competition and legal hassles remained as major headwinds. (You can read the full research report on Alphabet here>>)
Novo Nordisk shares have been laggards this year, as the Danish pharmaceutical giant has been grappling with a number of a company-specific issues on top of the unfavorable political/regulatory backdrop for the space as a whole. The company's strong presence in the Diabetes Care market and focus on therapeutic proteins within insulin is a big positive. To that end, Victoza remains a key growth area for the company. But a slew of patent expirations, growing pricing pressures for a number of its drugs and the recent decision to discontinue the development of liraglutide as a joint therapy to insulin in type I diabetes remain headwinds. The Zacks analyst discusses the pros & cons of investing in Novo Nordisk shares at this stage. (You can read the full research report on Novo Nordisk here>>)
Enterprise Products Partners shares have performed in line with the broader market this year, but lagged the energy space as a whole on NGL pricing issues and the recent uptrend in long-term interest rates. These issues notwithstanding, the Zacks analyst likes the partnership's large scale and diverse midstream asset base and multi-billion dollar projects under construction, which are likely to support meaningful distribution growth. (You can read the full research report on Enterprise Products Partners here>>)
Other noteworthy reports we are featuring today include Twitter (TWTR), Textron (TXT) and Xerox (XRX).
Free Access: All Zacks Research Reports
Starting today, you are invited to download in-depth analysis reports covering more than 1,000 of the most widely followed stocks. Valued at $25 each, they are yours to consult over the next 30 days absolutely free. They feature sensitive Zacks Rank information on each stock that you won't find anywhere else. See the reports free >>
You can find all of today's stock research reports here>>
Director of Research
Note: If you want an email notification each time Sheraz publishes a new article, please click here>>>